An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans
2007
Аутори
Bonassi, StefanoZnaor, Ariana
Ceppi, Marcello
Lando, Cecilia
Chang, Wushou Peter
Holland, Nina
Kirsch-Volders, Micheline
Zeiger, Errol
Ban, Sadayuki
Barale, Roberto
Bigatti, Maria Paola
Bolognesi, Claudia
Cebulska-Wasilewska, Antonina
Fabianova, Eleonora
Fucic, Alexandra
Hagmar, Lars
Joksić, Gordana
Martelli, Antonietta
Migliore, Lucia
Mirkova, Ekaterina
Scarfi, Maria Rosaria
Zijno, Andrea
Norppa, Hannu
Fenech, Michael
Чланак у часопису
Метаподаци
Приказ свих података о документуАпстракт
The frequency of micronuclei (MN) in peripheral blood lymphocytes (PBL) is extensively used as a biomarker of chromosomal damage and genome stability in human populations. Much theoretical evidence has been accumulated supporting the causal role of MN induction in cancer development, although prospective cohort studies are needed to validate MN as a cancer risk biomarker. A total of 6718 subjects from of 10 countries, screened in 20 laboratories for MN frequency between 1980 and 2002 in ad hoc studies or routine cytogenetic surveillance, were selected from the database of the HUman MicroNucleus (HUMN) international collaborative project and followed up for cancer incidence or mortality. To standardize for the inter-laboratory variability subjects were classified according to the percentiles of MN distribution within each laboratory as low, medium or high frequency. A significant increase of all cancers incidence was found for subjects in the groups with medium (RR = 1.84; 95% CI: 1.28-...2.66) and high MN frequency (RR = 1.53; 1.04-2.25). The same groups also showed a decreased cancer-free survival, i.e. P = 0.001 and P = 0.025, respectively. This association was present in all national cohorts and for all major cancer sites, especially urogenital (RR = 2.80; 1.17-6.73) and gastro-intestinal cancers (RR = 1.74; 1.01-4.71). The results from the present study provide preliminary evidence that MN frequency in PBL is a predictive biomarker of cancer risk within a population of healthy subjects. The current wide-spread use of the MN assay provides a valuable opportunity to apply this assay in the planning and validation of cancer surveillance and prevention programs.
Извор:
Carcinogenesis, 2007, 28, 3, 625-631
DOI: 10.1093/carcin/bgl177
ISSN: 0143-3334
PubMed: 16973674
WoS: 000245351100012
Scopus: 2-s2.0-34047154552
Колекције
Институција/група
VinčaTY - JOUR AU - Bonassi, Stefano AU - Znaor, Ariana AU - Ceppi, Marcello AU - Lando, Cecilia AU - Chang, Wushou Peter AU - Holland, Nina AU - Kirsch-Volders, Micheline AU - Zeiger, Errol AU - Ban, Sadayuki AU - Barale, Roberto AU - Bigatti, Maria Paola AU - Bolognesi, Claudia AU - Cebulska-Wasilewska, Antonina AU - Fabianova, Eleonora AU - Fucic, Alexandra AU - Hagmar, Lars AU - Joksić, Gordana AU - Martelli, Antonietta AU - Migliore, Lucia AU - Mirkova, Ekaterina AU - Scarfi, Maria Rosaria AU - Zijno, Andrea AU - Norppa, Hannu AU - Fenech, Michael PY - 2007 UR - https://vinar.vin.bg.ac.rs/handle/123456789/3178 AB - The frequency of micronuclei (MN) in peripheral blood lymphocytes (PBL) is extensively used as a biomarker of chromosomal damage and genome stability in human populations. Much theoretical evidence has been accumulated supporting the causal role of MN induction in cancer development, although prospective cohort studies are needed to validate MN as a cancer risk biomarker. A total of 6718 subjects from of 10 countries, screened in 20 laboratories for MN frequency between 1980 and 2002 in ad hoc studies or routine cytogenetic surveillance, were selected from the database of the HUman MicroNucleus (HUMN) international collaborative project and followed up for cancer incidence or mortality. To standardize for the inter-laboratory variability subjects were classified according to the percentiles of MN distribution within each laboratory as low, medium or high frequency. A significant increase of all cancers incidence was found for subjects in the groups with medium (RR = 1.84; 95% CI: 1.28-2.66) and high MN frequency (RR = 1.53; 1.04-2.25). The same groups also showed a decreased cancer-free survival, i.e. P = 0.001 and P = 0.025, respectively. This association was present in all national cohorts and for all major cancer sites, especially urogenital (RR = 2.80; 1.17-6.73) and gastro-intestinal cancers (RR = 1.74; 1.01-4.71). The results from the present study provide preliminary evidence that MN frequency in PBL is a predictive biomarker of cancer risk within a population of healthy subjects. The current wide-spread use of the MN assay provides a valuable opportunity to apply this assay in the planning and validation of cancer surveillance and prevention programs. T2 - Carcinogenesis T1 - An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans VL - 28 IS - 3 SP - 625 EP - 631 DO - 10.1093/carcin/bgl177 ER -
@article{ author = "Bonassi, Stefano and Znaor, Ariana and Ceppi, Marcello and Lando, Cecilia and Chang, Wushou Peter and Holland, Nina and Kirsch-Volders, Micheline and Zeiger, Errol and Ban, Sadayuki and Barale, Roberto and Bigatti, Maria Paola and Bolognesi, Claudia and Cebulska-Wasilewska, Antonina and Fabianova, Eleonora and Fucic, Alexandra and Hagmar, Lars and Joksić, Gordana and Martelli, Antonietta and Migliore, Lucia and Mirkova, Ekaterina and Scarfi, Maria Rosaria and Zijno, Andrea and Norppa, Hannu and Fenech, Michael", year = "2007", abstract = "The frequency of micronuclei (MN) in peripheral blood lymphocytes (PBL) is extensively used as a biomarker of chromosomal damage and genome stability in human populations. Much theoretical evidence has been accumulated supporting the causal role of MN induction in cancer development, although prospective cohort studies are needed to validate MN as a cancer risk biomarker. A total of 6718 subjects from of 10 countries, screened in 20 laboratories for MN frequency between 1980 and 2002 in ad hoc studies or routine cytogenetic surveillance, were selected from the database of the HUman MicroNucleus (HUMN) international collaborative project and followed up for cancer incidence or mortality. To standardize for the inter-laboratory variability subjects were classified according to the percentiles of MN distribution within each laboratory as low, medium or high frequency. A significant increase of all cancers incidence was found for subjects in the groups with medium (RR = 1.84; 95% CI: 1.28-2.66) and high MN frequency (RR = 1.53; 1.04-2.25). The same groups also showed a decreased cancer-free survival, i.e. P = 0.001 and P = 0.025, respectively. This association was present in all national cohorts and for all major cancer sites, especially urogenital (RR = 2.80; 1.17-6.73) and gastro-intestinal cancers (RR = 1.74; 1.01-4.71). The results from the present study provide preliminary evidence that MN frequency in PBL is a predictive biomarker of cancer risk within a population of healthy subjects. The current wide-spread use of the MN assay provides a valuable opportunity to apply this assay in the planning and validation of cancer surveillance and prevention programs.", journal = "Carcinogenesis", title = "An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans", volume = "28", number = "3", pages = "625-631", doi = "10.1093/carcin/bgl177" }
Bonassi, S., Znaor, A., Ceppi, M., Lando, C., Chang, W. P., Holland, N., Kirsch-Volders, M., Zeiger, E., Ban, S., Barale, R., Bigatti, M. P., Bolognesi, C., Cebulska-Wasilewska, A., Fabianova, E., Fucic, A., Hagmar, L., Joksić, G., Martelli, A., Migliore, L., Mirkova, E., Scarfi, M. R., Zijno, A., Norppa, H.,& Fenech, M.. (2007). An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. in Carcinogenesis, 28(3), 625-631. https://doi.org/10.1093/carcin/bgl177
Bonassi S, Znaor A, Ceppi M, Lando C, Chang WP, Holland N, Kirsch-Volders M, Zeiger E, Ban S, Barale R, Bigatti MP, Bolognesi C, Cebulska-Wasilewska A, Fabianova E, Fucic A, Hagmar L, Joksić G, Martelli A, Migliore L, Mirkova E, Scarfi MR, Zijno A, Norppa H, Fenech M. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. in Carcinogenesis. 2007;28(3):625-631. doi:10.1093/carcin/bgl177 .
Bonassi, Stefano, Znaor, Ariana, Ceppi, Marcello, Lando, Cecilia, Chang, Wushou Peter, Holland, Nina, Kirsch-Volders, Micheline, Zeiger, Errol, Ban, Sadayuki, Barale, Roberto, Bigatti, Maria Paola, Bolognesi, Claudia, Cebulska-Wasilewska, Antonina, Fabianova, Eleonora, Fucic, Alexandra, Hagmar, Lars, Joksić, Gordana, Martelli, Antonietta, Migliore, Lucia, Mirkova, Ekaterina, Scarfi, Maria Rosaria, Zijno, Andrea, Norppa, Hannu, Fenech, Michael, "An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans" in Carcinogenesis, 28, no. 3 (2007):625-631, https://doi.org/10.1093/carcin/bgl177 . .